COVID-19 and links to US researchers & funding

 

• First description of RECOMBINANT Wuhan corona virus with potential for human infection.

2015: A SARS-Like cluster… work performed in NC & ?Wuhan

“On the basis of these findings, we synthetically re-derived an infectious full-length SHC014 recombinant virus and demonstrate robust viral replication both in vitro and in vivo.”

 

AUTHORS include:

• Zhengli-Li Shi; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China – provided the Corona study virus

• RS Baric; Gillings School of Global Public Health, Department of Epidemiology & Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

 

• Funded by: National Institute ofAllergy & Infectious Disease and the National Institute of Aging of the US National Institutes of Health (NIH) and by the National Natural Science Foundation of China

(Z.-L.S.) and 31470260 (X.-Y.G.), and by USAID-EPT-PREDICT funding from

EcoHealth Alliance (Z.-L.S.).

 

From BARIC – CV selected info:

MEETINGS

1. SARS CoV Pathogenesis and Reverse Genetics. Jan 6-11th, 2004. Keystone Colorado. Invited speaker: Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators.

2. SARS-CoV Reverse Genetics, Beijing, China. July 2004.

3. Rewiring Coronavirus Genomes, Positive Strand RNA Virus Meeting, Washington, DC, May 2007

4. SARS-CoV Pathogenesis, Vaccine Design and Therapeutics, NIH Advisory Meeting and Planning Committee, Oct 1-2, 2007.

110.Vaccines and Adjuvants for Emerging Infectious Diseases. Invited Speaker. Montego Bay Jamaica. May 2011

1. WHO. Geneva Switzerland. Invited Speaker. June 2011.

 

PATENTS

UNC Patent/Invention Reports

A. US. Patent No. 6,593,111. 2003. Ralph S. Baric, Boyd Yount. Directional Assembly of

Large Viral Genomes and Chromosomes.

B. US Patent No. 7,279,327, 2007. Ralph S. Baric, Boyd Yount, Kristopher Curtis. Methods

for Producing Recombinant Coronavirus

C. US Patent No.7,618,802. Ralph S. Baric, Kristopher Curtis, Rhonda Roberts, Boyd Yount.

Methods and Compositions for Infectious cDNA of SARS Coronavirus.

 

VACCINES

National Institutes of Health, Allergy and Infectious Diseases. P01 AI059443-05.

Developing vaccine candidates for the SARS Coronavirus. RS Baric, PI 30% effort.

Total direct costs: $9,025,984; 5/1/05-1/31/11.

 

Baric R.S., Sheahan T, Deming D, Donaldson E, Yount B, Sims AC, Roberts RS,

Frieman M, Rockx B. 2006. SARS coronavirus vaccine development. Adv Exp Med

Biol. 581:553-60. PMID: 17037597

https://www.ncbi.nlm.nih.gov/pubmed/26552008

https://sph.unc.edu/files/2016/09/CV_Ralph_Baric.pdf

 

FUNDING: from acknowledgements:

Research in this manuscript was supported by grants from the

• National Institute of Allergy & Infectious Disease and the National Institute of Aging of the US National Institutes of Health (NIH) &

• National Natural Science Foundation of China awards &

• USAID-EPT-PREDICT funding from EcoHealth Alliance (Z.-L.S.).

https://www.ncbi.nlm.nih.gov/pubmed/26552008

 

From Gates Foundation Awards to Gillings School of Global Public Health - Water Institute

( Same School of Public Health as Baric)

2015 Feb: 24,750 + 267,978 = $292,728

2016 July: 21,984 + 687,319 = $709,303

2018 Sept: 27,968 =$ 27,968

None before or since.

https://www.gatesfoundation.org/search#q/k=Gillings

 

Just posted last bread USAID program shut down 2019 - GREAT!

https://8kun.top/qresearch/res/8692503.html#8692732